Phase II failures: 2008–2010
The DOI matches its Crossref record.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, the decreasing success rate of drugs entering clinical trials (29) suggests that the pharmacology of target-based drug candidates predicts their therapeutic efficacy and toxicity poorly.”
From Cytokine Response Is Determined by Duration of Receptor and Signal Transducers and Activators of Transcription 3 (STAT3) Activation (2013) · cites this paper as [29]
In the citing paper
“In the development of pharmaceutical drugs over 80% fail to reach ‘Phase III’ effectiveness trials, even after considerable investment [4].”
From Exploratory studies to decide whether and how to proceed with full-scale evaluations of public health interventions: a systematic review of guidance (2018) · cites this paper as [4]
Citations
Cites
Still being checked.
Cited by
Believe it or not: how much can we rely on published data on potential drug targets?
Prinz, F., Schlange, T., & Asadullah, K. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3439-c1 · Cited by 1,888
Gao, H., Korn, J. M., Ferretti, S., Monahan, J. E., Wang, Y., Singh, M., Zhang, C., Schnell, C., Yang, G., Zhang, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3954 · Cited by 1,393
Large-scale prediction and testing of drug activity on side-effect targets
Lounkine, E., Keiser, M. J., Whitebread, S., Mikhailov, D., Hamon, J., Jenkins, J. L., Lavan, P., Weber, E., Doak, A. K., Côté, S., et al. (2012) · Nature · doi:10.1038/nature11159 · Cited by 881
Validating therapeutic targets through human genetics
Plenge, R. M., Scolnick, E. M., & Altshuler, D. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4051 · Cited by 712
Morgan, P., Van Der Graaf, P. H., Arrowsmith, J., Feltner, D. E., Drummond, K. S., Wegner, C. D., & Street, S. D. A. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2011.12.020 · Cited by 692
Self-citationInterrogating open issues in cancer precision medicine with patient-derived xenografts
Byrne, A. T., Alférez, D. G., Amant, F., Annibali, D., Arribas, J., Biankin, A. V., Bruna, A., Budinská, E., Caldas, C., Chang, D. K., et al. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.140 · Cited by 657
Drug repurposing: a promising tool to accelerate the drug discovery process
Parvathaneni, V., Kulkarni, N. S., Muth, A., & Gupta, V. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.06.014 · Cited by 597
Screening out irrelevant cell-based models of disease
Horvath, P., Aulner, N., Bickle, M., Davies, A. M., Nery, E. D., Ebner, D., Montoya, M. C., Östling, P., Pietiäinen, V., Price, L. S., et al. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.175 · Cited by 525
Drug discovery in pharmaceutical industry: productivity challenges and trends
Khanna, I. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.05.007 · Cited by 479
Multiple hypothesis testing in experimental economics
List, J. A., Shaikh, A. M., & Xu, Y. (2019) · Experimental Economics · doi:10.1007/s10683-018-09597-5 · Cited by 463
Animal models in translational medicine: Validation and prediction
Denayer, T., Stöhr, T., & Roy, M. V. (2014) · European Journal of Molecular & Clinical Medicine · doi:10.1016/j.nhtm.2014.08.001 · Cited by 448
Phenotypic screens as a renewed approach for drug discovery
Zheng, W., Thorne, N., & McKew, J. C. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.07.001 · Cited by 423
Duan, X., Xiao, J., Yin, Q., Zhang, Z., Yu, H., Mao, S., & Li, Y. (2013) · ACS Nano · doi:10.1021/nn4010796 · Cited by 379
In vitro models for the prediction of in vivo performance of oral dosage forms
Kostewicz, E. S., Abrahamsson, B., Brewster, M., Brouwers, J., Butler, J., Carlert, S., Dickinson, P. A., Dressman, J., Holm, R., Klein, S., et al. (2014) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2013.08.024 · Cited by 373
Drugs, Devices, and the FDA: Part 1
Van Norman, G. A. (2016) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2016.03.002 · Cited by 366
A microRNA miR-34a-Regulated Bimodal Switch Targets Notch in Colon Cancer Stem Cells
Bu, P., Chen, K.-Y., Chen, J. H., Wang, L., Walters, J., Shin, Y. J., Goerger, J. P., Sun, J., Witherspoon, M., Rakhilin, N., et al. (2013) · Cell Stem Cell · doi:10.1016/j.stem.2013.03.002 · Cited by 357
Cancer drug discovery by repurposing: teaching new tricks to old dogs
Gupta, S. C., Sung, B., Prasad, S., Webb, L. J., & Aggarwal, B. B. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.06.005 · Cited by 340
Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS)
Varma, M. V., Steyn, S. J., Allerton, C., & El-Kattan, A. F. (2015) · Pharmaceutical Research · doi:10.1007/s11095-015-1749-4 · Cited by 334
The future of molecular dynamics simulations in drug discovery
Borhani, D. W., & Shaw, D. E. (2012) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-011-9517-y · Cited by 313
“[11] Two-thirds of recent Phase III failures are due to inadequate efficacy [12], as are more than half of Phase II [13] and * 16% of Phase I [14] failures.”
BackgroundReproducible Research Practices and Transparency across the Biomedical Literature
Iqbal, S. A., Wallach, J. D., Khoury, M. J., Schully, S. D., & Ioannidis, J. P. A. (2016) · PLOS Biology · doi:10.1371/journal.pbio.1002333 · Cited by 310
Wang, X., Pan, C., Gong, J., Liu, X., & Li, H. (2016) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5b00690 · Cited by 290
When Quality Beats Quantity: Decision Theory, Drug Discovery, and the Reproducibility Crisis
Scannell, J. W., & Bosley, J. (2016) · PLOS ONE · doi:10.1371/journal.pone.0147215 · Cited by 279
Risk in vaccine research and development quantified
Pronker, E. S., Weenen, T. C., Commandeur, H., Claassen, E. H. J. H. M., & Osterhaus, A. D. M. E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057755 · Cited by 253
Drug repositioning for personalized medicine
Li, Y. Y., & Jones, S. J. (2012) · Genome Medicine · doi:10.1186/gm326 · Cited by 248
Rodent models of post-traumatic stress disorder: behavioral assessment
Verbitsky, A., Dopfel, D., & Zhang, N. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-0806-x · Cited by 247
Hallingberg, B., Turley, R., Segrott, J., Wight, D., Craig, P., Moore, L., Murphy, S., Robling, M., Simpson, S. A., & Moore, G. (2018) · Pilot and Feasibility Studies · doi:10.1186/s40814-018-0290-8 · Cited by 248
Improving the odds of drug development success through human genomics: modelling study
Hingorani, A. D., Kuan, V., Finan, C., Kruger, F. A., Gaulton, A., Chopade, S., Sofat, R., MacAllister, R. J., Overington, J. P., Hemingway, H., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-54849-w · Cited by 247
Therapeutic Nanoparticles in Clinics and Under Clinical Evaluation
Schütz, C. A., Juillerat-Jeanneret, L., Mueller, H., Lynch, I., & Riediker, M. (2013) · Nanomedicine · doi:10.2217/nnm.13.8 · Cited by 242
What makes a good drug target?
Gashaw, I., Ellinghaus, P., Sommer, A., & Asadullah, K. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.09.007 · Cited by 240
Market size and innovation: Effects of Medicare Part D on pharmaceutical research and development
Blume-Kohout, M. E., & Sood, N. (2013) · Journal of Public Economics · doi:10.1016/j.jpubeco.2012.10.003 · Cited by 225
Esch, M. B., Ueno, H., Applegate, D. R., & Shuler, M. L. (2016) · Lab on a Chip · doi:10.1039/c6lc00461j · Cited by 222
Sacks, L. V., Shamsuddin, H. H., Yasinskaya, Y. I., Bouri, K., Lanthier, M. L., & Sherman, R. E. (2014) · JAMA · doi:10.1001/jama.2013.282542 · Cited by 214
Stable isotope-resolved metabolomics and applications for drug development
Fan, T. W.-M., Lorkiewicz, P. K., Sellers, K., Moseley, H. N. B., Higashi, R. M., & Lane, A. N. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.12.007 · Cited by 209
Sanmamed, M. F., Chester, C., Melero, I., & Kohrt, H. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw041 · Cited by 207
Improving and Accelerating Drug Development for Nervous System Disorders
Pankevich, D. E., Altevogt, B. M., Dunlop, J., Gage, F. H., & Hyman, S. E. (2014) · Neuron · doi:10.1016/j.neuron.2014.10.007 · Cited by 206
Look back in anger – what clinical studies tell us about preclinical work
Hartung, T. (2013) · ALTEX · doi:10.14573/altex.2013.3.275 · Cited by 200
“Omics”-Informed Drug and Biomarker Discovery: Opportunities, Challenges and Future Perspectives
Matthews, H., Hanison, J., & Nirmalan, N. (2016) · Proteomes · doi:10.3390/proteomes4030028 · Cited by 191
Pragmatic issues in biomarker evaluation for targeted therapies in cancer
de Gramont, A., Watson, S., Ellis, L. M., Rodón, J., Tabernero, J., de Gramont, A., & Hamilton, S. R. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.202 · Cited by 176
Impact of Lipophilic Efficiency on Compound Quality
Tarcsay, Á., Nyíri, K., & Keserű, G. M. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201388p · Cited by 164
Advancing Biological Understanding and Therapeutics Discovery with Small-Molecule Probes
Schreiber, S. L., Kotz, J. D., Li, M., Aubé, J., Austin, C. P., Reed, J. C., Rosen, H., White, E. L., Sklar, L. A., Lindsley, C. W., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.023 · Cited by 169
Braun, D. A., Fribourg, M., & Sealfon, S. C. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.386573 · Cited by 168
Shah, D. K., Haddish-Berhane, N., & Betts, A. (2012) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-012-9276-y · Cited by 160
The golden retriever model of Duchenne muscular dystrophy
Kornegay, J. N. (2017) · Skeletal Muscle · doi:10.1186/s13395-017-0124-z · Cited by 160
The influence of the 'organizational factor' on compound quality in drug discovery
Leeson, P. D., & St-Gallay, S. A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3552 · Cited by 162
Translating slow-binding inhibition kinetics into cellular and in vivo effects
Walkup, G. K., You, Z., Ross, P. L., Allen, E. K. H., Daryaee, F., Hale, M. R., O’Donnell, J. C., Ehmann, D. E., Schuck, V., Buurman, E. T., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1796 · Cited by 160
2D Layered Double Hydroxide Nanoparticles: Recent Progress toward Preclinical/Clinical Nanomedicine
Cao, Z., Li, B., Sun, L., Li, L., Xu, Z. P., & Gu, Z. (2019) · Small Methods · doi:10.1002/smtd.201900343 · Cited by 157
Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications
Shih, H.-P., Zhang, X., & Aronov, A. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.194 · Cited by 160
Koutsoukas, A., Lowe, R., KalantarMotamedi, Y., Mussa, H. Y., Klaffke, W., Mitchell, J. B. O., Glen, R. C., & Bender, A. (2013) · Journal of Chemical Information and Modeling · doi:10.1021/ci300435j · Cited by 147
Comparison Study of Computational Prediction Tools for Drug-Target Binding Affinities
Thafar, M., Raies, A. B., Albaradei, S., Essack, M., & Bajic, V. B. (2019) · Frontiers in Chemistry · doi:10.3389/fchem.2019.00782 · Cited by 144
Tissue chips – innovative tools for drug development and disease modeling
Low, L. A., & Tagle, D. A. (2017) · Lab on a Chip · doi:10.1039/c7lc00462a · Cited by 144
Arrowsmith, J. E. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3630 · Cited by 140
Self-citationiPSC-Derived Hepatocytes as a Platform for Disease Modeling and Drug Discovery
Corbett, J., & Duncan, S. A. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00265 · Cited by 150
Peptide-based PET quantifies target engagement of PD-L1 therapeutics
Kumar, D., Lisok, A., Dahmane, E., McCoy, M., Shelake, S., Chatterjee, S., Allaj, V., Sysa‐Shah, P., Wharram, B. L., Lesniak, W. G., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci122216 · Cited by 142
Drug development and clinical trials—the path to an approved cancer drug
Rubin, E. H., & Gilliland, D. G. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.22 · Cited by 135
A Multi-center Study on the Reproducibility of Drug-Response Assays in Mammalian Cell Lines
Niepel, M., Hafner, M., Mills, C. E., Subramanian, K., Williams, E. H., Chung, M., Gaudio, B., Barrette, A. M., Stern, A. D., Hu, B., et al. (2019) · Cell Systems · doi:10.1016/j.cels.2019.06.005 · Cited by 133
The changing landscape in translocator protein (TSPO) function
Selvaraj, V., & Stocco, D. M. (2015) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2015.02.007 · Cited by 142
Organs-on-chips: Progress, challenges, and future directions
Low, L. A., & Tagle, D. A. (2017) · Experimental Biology and Medicine · doi:10.1177/1535370217700523 · Cited by 133
Reproducibility and Research Integrity
Resnik, D. B., & Shamoo, A. E. (2016) · Accountability in Research · doi:10.1080/08989621.2016.1257387 · Cited by 151
Pharmacotherapy of amphetamine‐type stimulant dependence: An update
Brensilver, M., Heinzerling, K. G., & Shoptaw, S. (2013) · Drug and Alcohol Review · doi:10.1111/dar.12048 · Cited by 124
Buscher, K., Ehinger, E., Gupta, P., Pramod, A. B., Wolf, D., Tweet, G., Pan, C., Mills, C. D., Lusis, A. J., & Ley, K. (2017) · Nature Communications · doi:10.1038/ncomms16041 · Cited by 123
Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape
Olaussen, K. A., & Postel-Vinay, S. C. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw321 · Cited by 132
A high content screening assay to predict human drug-induced liver injury during drug discovery
Persson, M., Løye, A. F., Mow, T. J., & Hornberg, J. J. (2013) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2013.08.001 · Cited by 120
Malik, V., Kalakoti, Y., & Sundar, D. (2021) · BMC Genomics · doi:10.1186/s12864-021-07524-2 · Cited by 139
Monaco, G., van Dam, S., Casal Novo Ribeiro, J. L., Larbi, A., & de Magalhães, J. P. (2015) · BMC Evolutionary Biology · doi:10.1186/s12862-015-0534-7 · Cited by 116
Chen, M., Hong, H., Fang, H., Kelly, R., Zhou, G., Borlak, J., & Tong, W. (2013) · Toxicological Sciences · doi:10.1093/toxsci/kft189 · Cited by 115
The risks of risk aversion in drug regulation
Eichler, H., Bloechl‐Daum, B., Brasseur, D. J., Breckenridge, A. M., Leufkens, H. G. M., Raine, J. M., Salmonson, T., Schneider, C. K., & Rasi, G. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4129 · Cited by 115
Exploratory toxicology as an integrated part of drug discovery. Part I: Why and how
Hornberg, J. J., Laursen, M., Brenden, N., Persson, M., Thougaard, A., Toft, D. B., & Mow, T. J. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.12.008 · Cited by 125
DNA binders in clinical trials and chemotherapy
Ali, A., & Bhattacharya, S. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.05.030 · Cited by 134
What makes a good drug target?
Gashaw, I., Ellinghaus, P., Sommer, A., & Asadullah, K. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.12.008 · Cited by 122
Bernetti, M., Cavalli, A., & Mollica, L. (2017) · MedChemComm · doi:10.1039/c6md00581k · Cited by 120
Mechanistic biomarkers for clinical decision making in rheumatic diseases
Robinson, W. H., Lindstrom, T. M., Cheung, R. K., & Sokolove, J. (2013) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2013.14 · Cited by 109
Toxicity testing in the 21st century beyond environmental chemicals
Rovida, C. (2015) · ALTEX · doi:10.14573/altex.1506201 · Cited by 106
How necessary are animal models for modern drug discovery?
Singh, V. K., & Seed, T. M. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1972255 · Cited by 129
Reproducibility of research and preclinical validation: problems and solutions
Pusztai, L., Hatzis, C., & André, F. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.171 · Cited by 114
A recellularized human colon model identifies cancer driver genes
Chen, H. J., Wei, Z., Sun, J., Bhattacharya, A., Savage, D. J., Serda, R., Mackeyev, Y., Curley, S. A., Bu, P., Wang, L., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3586 · Cited by 101
Advancing the Drug Discovery and Development Process
Nicolaou, K. C. (2014) · Angewandte Chemie · doi:10.1002/ange.201404761 · Cited by 117
Schomberg, D. T., Tellez, A., Meudt, J. J., Brady, D. A., Dillon, K. N., Arowolo, F. K., Wicks, J., Rousselle, S. D., & Shanmuganayagam, D. (2016) · Toxicologic Pathology · doi:10.1177/0192623315618292 · Cited by 97
Appraising iniparib, the PARP inhibitor that never was—what must we learn?
Mateo, J., Ong, M., Tan, D. S. P., Gonzalez, M. A., & de Bono, J. S. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.177 · Cited by 96
Valdez, J., Cook, C. D., Ahrens, C. C., Wang, A. J.-S., Brown, A., Kumar, M. P., Stockdale, L., Rothenberg, D., Renggli, K., Gordon, E. A., et al. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.03.030 · Cited by 94
Sutherland, J. J., Webster, Y., Willy, J. A., Searfoss, G. H., Goldstein, K. M., Irizarry, A. R., Hall, D. G., & Stevens, J. L. (2017) · The Pharmacogenomics Journal · doi:10.1038/tpj.2017.17 · Cited by 97
Advancing the Drug Discovery and Development Process
Nicolaou, K. C. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201404761 · Cited by 117
Reproducibility Crisis: Are We Ignoring Reaction Norms?
Voelkl, B., & Würbel, H. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.05.003 · Cited by 103
Sams‐Dodd, F. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.10.010 · Cited by 97
Using PDX for Preclinical Cancer Drug Discovery: The Evolving Field
Williams, J. A. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7030041 · Cited by 103
Phenotype-driven precision oncology as a guide for clinical decisions one patient at a time
Chia, S., Low, J.-L., Zhang, X., Kwang, X.-L., Chong, F.-T., Sharma, A., Bertrand, D., Toh, S. Y., Leong, H. S., Thangavelu, M. T., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00451-5 · Cited by 94
Hao, C., Wang, L., Peng, S., Cao, M., Li, H., Hu, J., Huang, X., Liu, W., Zhang, H., Wu, S., et al. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.11.024 · Cited by 95
Allison, M. (2012) · Nature Biotechnology · doi:10.1038/nbt.2083 · Cited by 91
The compromise of virtual screening and its impact on drug discovery
Slater, O., & Kontoyianni, M. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1604677 · Cited by 92
Characterization of Differential Tissue Abundance of Major Non-CYP Enzymes in Human
Basit, A., Neradugomma, N. K., Wolford, C. C., Fan, P. W., Murray, B. P., Takahashi, R., Khojasteh, S. C., Smith, B. J., Heyward, S. A., Totah, R. A., et al. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00559 · Cited by 92
Pun, F. W., Leung, G. H. D., Leung, H.-W., Liu, B. H. M., Long, X., Ozerov, I. V., Wang, J., Ren, F., Aliper, A. M., Izumchenko, E., et al. (2022) · Aging · doi:10.18632/aging.203960 · Cited by 97
Drug–Target Association Kinetics in Drug Discovery
IJzerman, A. P., & Guo, D. M. (2019) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2019.04.004 · Cited by 90
The Impact of Chemical Probes in Drug Discovery: A Pharmaceutical Industry Perspective
Garbaccio, R. M., & Parmee, E. R. (2016) · Cell chemical biology · doi:10.1016/j.chembiol.2015.11.011 · Cited by 81
Why and how have drug discovery strategies in pharma changed? What are the new mindsets?
Mignani, S. M., Huber, S., Tomás, H., Rodrigues, J., & Majoral, J. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.09.007 · Cited by 99
Sutherland, M. L., Fabre, K. M., & Tagle, D. A. (2013) · Stem Cell Research & Therapy · doi:10.1186/scrt361 · Cited by 81
Effect of impact factor and discipline on journal data sharing policies
Resnik, D. B., Morales, M., Landrum, R. E., Shi, M., Minnier, J., Vasilevsky, N., & Champieux, R. (2019) · Accountability in Research · doi:10.1080/08989621.2019.1591277 · Cited by 85
Methodology of oral formulation selection in the pharmaceutical industry
Kuentz, M., Holm, R., & Elder, D. P. (2015) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2015.12.008 · Cited by 93
Zhang, J. D., Berntenis, N., Roth, A., & Ebeling, M. (2014) · The Pharmacogenomics Journal · doi:10.1038/tpj.2013.39 · Cited by 79
In silico prediction of chemical mechanism of action via an improved network‐based inference method
Wu, Z., Lü, W., Wu, D., Luo, A., Bian, H., Li, J., Li, W., Liu, G., Huang, J. Y., Cheng, F., et al. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13629 · Cited by 85
Murine Models of Inflammatory Bowel Disease (IBD): Challenges of Modeling Human Disease
DeVoss, J., & Diehl, L. J. (2013) · Toxicologic Pathology · doi:10.1177/0192623313509729 · Cited by 89
Ye, F. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00052 · Cited by 83
Metadata
- Authors
- Arrowsmith, J.
- Affiliations
- Thomson Reuters (United Kingdom) (GB)
- Corresponding author
- Arrowsmith, John
- Venue
- Nature Reviews Drug Discovery
- Published
- 2011-04-29
- Volume
- 10
- Issue
- 5
- Pages
- 328-329
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2065540447
- Cited by
- 622
- References
- 0
- Citations by year
- 2026: 12 · 2025: 18 · 2024: 22 · 2023: 14 · 2022: 21 · 2021: 25 · 2020: 36 · 2019: 44 · 2018: 37 · 2017: 54 · 2016: 64 · 2015: 66 · 2014: 66 · 2013: 88 · 2012: 41
- Type
- other
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Science, Research, and Medicine
- Keywords
- drug development failure, clinical trial attrition, drug repurposing, translational research
- MeSH terms
- Drug Industry, Pharmaceutical Preparations, Humans, Drug Design, Treatment Failure, Clinical Trials, Phase II as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.